New supplement aims to slow Parkinson's by boosting brain antioxidant levels
NCT ID NCT07064005
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 30 times
Summary
This early-phase study tests whether a supplement called gamma-glutamylcysteine (GGC) can increase levels of the brain's master antioxidant, glutathione, in people with early Parkinson's disease. Researchers will measure changes in brain chemistry, motor skills, thinking abilities, and gut health over the course of supplementation. The trial enrolls 12 adults aged 50–80 with confirmed Parkinson's and no dementia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSONS DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Presbyterian Hospital
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.